Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Lasa Supergenerics Ltd

Pharmaceuticals & Biotechnology | Small Cap

Lasa Supergenerics Ltd Health Insights
Health Score : 4.39Health Score : 4.39

Lasa Supergenerics Ltd, operating in the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strengths in solvency, driven by a solid equity base. However, liquidity is a significant concern, with all ratios indicating poor short-term financial health. Growth metrics are volatile, with high operating profit and EPS growth offset by declines in asset and revenue growth. Coverage ratios are weak, reflecting challenges in meeting interest obligations. Profitability is also a concern, with low margins and returns. While the company shows positive trends in specific growth areas, the overall financial health is hampered by liquidity and profitability issues, suggesting potential risks for investors.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Lasa Supergenerics Ltd Health Insights
Health Score : 4.39Health Score : 4.39

Lasa Supergenerics Ltd, operating in the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strengths in solvency, driven by a solid equity base. However, liquidity is a significant concern, with all ratios indicating poor short-term financial health. Growth metrics are volatile, with high operating profit and EPS growth offset by declines in asset and revenue growth. Coverage ratios are weak, reflecting challenges in meeting interest obligations. Profitability is also a concern, with low margins and returns. While the company shows positive trends in specific growth areas, the overall financial health is hampered by liquidity and profitability issues, suggesting potential risks for investors.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Highly Undervalued

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Highly Undervalued

P/E RATIO (TTM)

-1.16

Highly Undervalued

Industry Median

23.93

Highly Undervalued
Highly Undervalued

Small Cap Median

23.93

Highly Undervalued

P/E RATIO

-2.61

P/B RATIO

0.46

Undervalued

Industry Median

2.53

Undervalued
Undervalued

Small Cap Median

2.53

Undervalued

P/S RATIO

0.27

Highly Undervalued

Industry Median

1.35

Highly Undervalued
Highly Undervalued

Small Cap Median

1.35

Highly Undervalued

Others

Highly Undervalued

PEG RATIO

0.10

Highly Undervalued
Highly Undervalued

EV/EBITDA RATIO

-9.41

Highly Undervalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹7.7 as on Jun 15, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 5.20

The company's growth ratios show significant volatility. While operating profit and EPS growth rates are strong, revenue, asset, and net income growth rates are weak. This suggests that the company's profitability improvements may not be sustainable without broader growth across all areas. The healthcare industry's dynamic nature requires consistent growth in revenue and assets to maintain a competitive edge.

PoorRevenue Growth RatePoor
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
PoorAsset Growth RatePoor
PoorNet Income Growth RatePoor
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate-31.84-5.11-2036.54-82.39
Operating Profit Growth Rate-65.96-137.5-133.33200-216.67
Earnings Per Share (EPS) Growth-123.39488.55-43.71-32.03130.51
Asset Growth Rate0.48-21.53-7.93-32.45-35.29
Net Income Growth Rate-121.74680-43.59-31.82126.67
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 4.00

The financial ratios reveal a mixed performance. While capital expenditures are well-managed, adjusted EPS, book value per share, and dividend per share are low. Cash EPS is moderate. This suggests challenges in generating consistent earnings and shareholder value. The healthcare sector's regulatory and competitive pressures can affect these ratios, requiring strategic financial management.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
ExcellentCapital Expenditures (CapEx)Excellent
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)0.6-4-2.80.2-2.6
Cash Earnings Per Share (Cash EPS)2-5.2-2.2-0.6-5.6
Book Value Per Share31.623.619.416.810
Dividend Per Share (DPS)0.310000
Capital Expenditures (CapEx)2.64.81.77.80.2
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 2.20

The company's profitability ratios are generally weak. Gross profit margin, return on capital employed, return on equity, operating margin, and net margin are all low. Return on assets is slightly better but still below average. This suggests challenges in generating profits from its operations and assets. The healthcare industry's competitive pressures and regulatory environment may contribute to these challenges.

PoorGross Profit MarginPoor
PoorReturn on Capital Employed (ROCE)Poor
PoorReturn on Equity (ROE)Poor
WeakReturn on Assets (ROA)Weak
PoorOperating MarginPoor
PoorNet MarginPoor
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin0.73-14.62-8.65-4.23-52
Return on Capital Employed (ROCE)1-12-6-1-18
Return on Equity (ROE)-3.16-33.05-22.68-17.86-68
Return on Assets (ROA)7.66-3.661.325.88-10.61
Operating Margin11.68-4.621.924.23-28
Net Margin-3.65-30-21.15-10.56-136
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 4.67

The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days are well-managed, turnover ratios for fixed assets, inventory, receivables, and capital are low. This suggests potential inefficiencies in asset utilization and working capital management. The healthcare industry's specific operational demands may influence these ratios, but improvements in asset turnover could enhance overall efficiency.

PoorFixed Asset Turnover RatioPoor
PoorInventory Turnover RatioPoor
PoorReceivables Turnover RatioPoor
ExcellentDays Sales in Inventory RatioExcellent
ExcellentReceivable DaysExcellent
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio11.090.952.090.45
Inventory Turnover Ratio9.3911.736.866.82.89
Receivables Turnover Ratio8.2212.3634.2755.9132.68
Days Sales in Inventory Ratio38.8731.1253.2153.68126.3
Receivable Days44.429.5310.656.5311.17
Capital Turnover Ratio0.771.11.071.690.5
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 2.00

The company's coverage ratios are weak, particularly concerning the interest coverage ratio. This indicates potential difficulties in meeting interest obligations, which could increase financial risk. The healthcare industry's capital-intensive nature requires careful management of debt and interest expenses to ensure financial stability.

PoorInterest Coverage RatioPoor
PoorEquity Dividend Coverage RatioPoor
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage RatioN/A-9.5-8.5-5.33N/A
Equity Dividend Coverage Ratio
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company's solvency position is strong, primarily due to a high equity ratio and low debt levels. This indicates a solid financial foundation and lower risk of financial distress. The company's reliance on equity rather than debt provides stability and resilience. However, it's important to monitor whether this capital structure supports optimal growth and profitability in the long term.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.110000
Debt to Equity Ratio0.120000
Equity Ratio0.891111
Debt To Asset Ratio0.10000
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 2.00

The company's liquidity position is weak, with all liquidity ratios indicating poor short-term financial health. This suggests potential difficulties in meeting immediate obligations and managing working capital. The lack of liquid assets may hinder operational flexibility and increase financial risk. While the healthcare industry can have unique working capital cycles, these ratios raise concerns about the company's ability to handle unforeseen expenses or invest in growth opportunities.

PoorCurrent RatioPoor
PoorQuick RatioPoor
PoorCash RatioPoor
PoorOperating Cash Flow RatioPoor
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio2.160.870.721.820.66
Quick Ratio1.790.570.370.470.55
Cash Ratio0.560.050.030.040.04
Operating Cash Flow Ratio0.29-0.370.04-0.170
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 6 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Medicamen Organics Ltd6.30-6.94Neutral-3.75-2.50-4.02
2Mono Pharmacare Ltd6.166.26Neutral8.001.753.00
3JFL Life Sciences Ltd6.079.43Neutral12.001.946.00
4Walpar Nutritions Ltd5.299.26Neutral6.662.093.00
5Mangalam Drugs and Organics Ltd4.50-1.07Neutral-15.00-27.68-44.00
6Lasa Supergenerics Ltd4.39-2.61Highly Undervalued-7.00-6.80-34.00
Management Assessment Summary
RedWeak Management

The management effectiveness of Lasa Supergenerics Ltd appears weak based on the available data due to negative profit, returns on equity, and inconsistent financial performance. The company has experienced fluctuating sales growth and negative profit margins, indicating operational inefficiencies. Despite an increase in promoter holding, the overall financial performance raises concerns about the management's effectiveness in driving sustainable growth and profitability.

Category Metric Value Assessment
PROS Promoter Holding 53.65% Indicates promoter confidence.
CONS ROCE -13.23% Suggests inefficient capital utilization.
ROE -20.22% Indicates poor return to shareholders.
Dividend Payout % 0.00 % Indicates company is not sharing profits with shareholders.
PoorFinancial Performance & GrowthPoor
PoorCapital Efficiency & ReturnsPoor
WeakFinancial Health & PrudenceWeak
AverageStrategic & Operational IndicatorsAverage
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Strategic & Operational Indicators

Risk Assessment Summary
RedWeak Risk

The risk assessment for Lasa Supergenerics Ltd indicates a high level of risk due to negative profitability, inconsistent sales growth, and negative returns on capital employed and equity. The volatility in quarterly sales and profit growth, combined with fluctuating operating profit margins, suggests instability. The decreased borrowings may indicate improved debt management but the overall financial health remains weak.

AverageAccounting quality red flagsAverage
AverageSegment performance volatilityAverage
AverageForeign exchange or interest rate exposureAverage
AverageRegulatory compliance cost trendsAverage
01.

Accounting quality red flags

02.

Segment performance volatility

03.

Foreign exchange or interest rate exposure

04.

Regulatory compliance cost trends

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe